# Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma

> **NCT04609046** · PHASE1 · RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 47 (estimated)

## Conditions studied

- Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System

## Interventions

- **PROCEDURE:** Bone Marrow Aspiration and Biopsy
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Echocardiography Test
- **DRUG:** Lenalidomide
- **PROCEDURE:** Lumbar Puncture
- **PROCEDURE:** Magnetic Resonance Imaging
- **DRUG:** Methotrexate
- **BIOLOGICAL:** Nivolumab
- **PROCEDURE:** Positron Emission Tomography
- **BIOLOGICAL:** Rituximab
- **PROCEDURE:** Ultrasound Imaging

## Key facts

- **NCT ID:** NCT04609046
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-05-24
- **Primary completion:** 2027-04-01
- **Final completion:** 2027-04-01
- **Target enrollment:** 47 (ESTIMATED)
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04609046

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04609046, "Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma". Retrieved via AI Analytics 2026-07-21 from https://api.ai-analytics.org/clinical/NCT04609046. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*